Generation Bio Long Term Debt 2020-2023 | GBIO

Generation Bio long term debt from 2020 to 2023. Long term debt can be defined as the sum of all long term debt fields.
Generation Bio Annual Long Term Debt
(Millions of US $)
2023 $
2022 $
2021 $
2020 $
2019 $
Generation Bio Quarterly Long Term Debt
(Millions of US $)
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.211B $0.006B
Generation Bio Co. is a genetic medicines company. It is focused on creating gene therapy for patients suffering from both rare and prevalent diseases. Generation Bio Co. is based in CAMBRIDGE, Mass.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $15.673B 5.66
Dr Reddy's Laboratories (RDY) India $12.551B 19.84
Aspen Pharmacare (APNHY) South Africa $5.574B 0.00
BridgeBio Pharma (BBIO) United States $5.208B 0.00
Bausch Health Cos (BHC) Canada $2.858B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.042B 14.20
Supernus Pharmaceuticals (SUPN) United States $1.695B 0.00
Taysha Gene Therapies (TSHA) United States $0.481B 0.00
Personalis (PSNL) United States $0.078B 0.00
Assembly Biosciences (ASMB) United States $0.072B 0.00
Acasti Pharma (ACST) Canada $0.028B 0.00
Sol-Gel Technologies (SLGL) Israel $0.024B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00